Beyond Regulatory Reform: How Biosimilar Development Is Reshaping Market Access and Manufacturing Strategy

The biosimilar landscape is undergoing fundamental transformation as regulatory agencies move beyond blanket requirements toward science-based development pathways. This session examines how recent regulatory reforms—particularly the UK MHRA's removal of default comparative efficacy trials and the EMA's evolving approach—are creating new competitive dynamics that extend far beyond development timelines.

Drawing on real-world implementation experiences and market analysis, this panel explores the strategic implications of regulatory simplification for manufacturers, healthcare systems, and patient access. Key focus areas include how streamlined pathways are driving manufacturing efficiency requirements, reshaping competitive positioning, and creating new opportunities for market entry.